PT Murni Sadar Tbk (MTMH) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of PT Murni Sadar Tbk IDR 464, price IDR 950, upside -51.2%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch PT Murni Sadar Tbk for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
53‑month range 837.99 IDR – 2,723 IDR · fair‑value band 347.98 IDR – 579.96 IDR · the 950.00 IDR price screens above the 463.97 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow PT Murni Sadar Tbk in your weekly email
Every Wednesday you see whether PT Murni Sadar Tbk is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PT Murni Sadar Tbk, together with its subsidiaries, provides health services and manages private hospitals in Indonesia.
Show more
PT Murni Sadar Tbk, together with its subsidiaries, provides health services and manages private hospitals in Indonesia. The company offers outpatient installation services, including specialist, family health, general, dental, tropical diseases, travel medicine, and pain clinics; laboratory services, such as clinical pathology, blood bank, biomolecular/PCR, microbiology, and anatomical pathology; radiotherapy, consists of LINAC, CT-simulator and immobilization, treatment planning system, and brachytherapy services. It also provides radiology services, including general X-Ray, ultrasonography (USG), mammography, 128 slice CT scan, 1.5 Tesla MRI, and interventional radiology; heart & vascular center, such as ECG, treadmill test, echocardiology, holter monitoring, and cardiac catheterization laboratory; endoscopy, contain esophagoscopy, gastroscopy, colonoscopy, bronchoscopy, and ERCP; medical rehabilitation, comprising physiotherapy, speech and occupation therapy, and orthotic prosthetic. In addition, the company offers general services, which includes emergency installation, and inpatient facility; intensive care; public facilities; operating theatres, ESWL, laporoscopic surgery, oncology, chemotherapy, pharmaceutical installations, medical checkup, lifestyle clinic, murni teguh IVF, home care, palliative care, EEG, EMG, and ambulance services; as well as operates IVF Centre. Further, it provides general facilities such as, auditorium, cafeteria, commercials area, fitness gym, and homestay. PT Murni Sadar Tbk was founded in 2010 and is based in Medan, Indonesia.
Stock analysis
PT Murni Sadar Tbk (MTMH) currently trades at 950.00 IDR, while our model-based Fair Value estimate is 463.97 IDR, implying the stock looks roughly 104.8% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 558.78 IDR per share, and 1 of the 14 models we run sit above the 950.00 IDR price.
Bear case: the Economic Profit group reads lowest at 130.28 IDR, and 13 of the 14 models stay below the price. Evidence for this calculation is low.
Scenario range: 347.98 IDR (bear) to 579.96 IDR (bull), the price of 950.00 IDR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
PT Murni Sadar Tbk reported revenue of 1.4T IDR in FY2025 versus 983B IDR in FY2021, a compound +8.4%/yr. Reported net income was 43.6B IDR in FY2025, compounding −23.9%/yr from FY2021.
Key figures
Market cap 2.0T IDR (≈ $110M) · P/E ratio 48.3 · P/S ratio 1.55 · EPS (TTM) 19.68 IDR · Dividend yield 0.3% · Net margin 3.2% · Return on equity 2.7% · Return on assets (EBIT) 7.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 31% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −51%, MTMH screens richer than that median.
Fair Value models
Bear 347.98 IDRFair Value 463.97 IDRBull 579.96 IDR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (12.67 IDR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+27.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.0%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.8%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−7.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−8.1%
Dividend (yield on the price)0.3%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 9%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 258 stocks
Beats the industry median on 3/13 measures
Overall it trails its industry peers.
Valuation
Quality Score45 · Below median
Fair Value upside−50% · Bottom 25%
Profitability
Return on equity (TTM)3% · Below median
Return on assets3% · Below median
Net margin (TTM)3% · Below median
Operating margin (TTM)7% · Below median
Growth and dividend
Revenue growth23% · Top 25%
Dividend yield (TTM)0.3% · Bottom 25%
Balance sheet
Debt / equity0.30× · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (TTM)48.3× · Priciest 25%
P/B1.30× · Cheaper than median
P/S (TTM)1.35× · Pricier than median
EV/EBITDA8.1× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)100· sector 28
PAST (return on equity)11· sector 31
HEALTH (low debt)85· sector 89
DIVIDEND (yield)5· sector 43
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is PT Murni Sadar Tbk (MTMH) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 463.97 IDR versus a price of 950.00 IDR, about −51% upside (overvalued).
What is the fair value of MTMH?
Our model-based fair value for PT Murni Sadar Tbk is 463.97 IDR (as of Sep 24, 2026), built from audited fundamentals. The current price: 950.00 IDR.
What is the quality score of MTMH?
PT Murni Sadar Tbk has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PT Murni Sadar Tbk (MTMH)?
Our model-based price target is the fair value of 463.97 IDR (as of Sep 24, 2026) from 14 valuation models. Cautious scenario 347.98 IDR, optimistic scenario 579.96 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the PT Murni Sadar Tbk stock forecast for 2026?
Our models put fair value at 463.97 IDR, about −51% upside versus a price of 950.00 IDR (overvalued). Cautious scenario 347.98 IDR, optimistic scenario 579.96 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of PT Murni Sadar Tbk (MTMH)?
PT Murni Sadar Tbk reported trailing-twelve-month revenue of about 1.4T IDR (latest available figure, as of Sep 24, 2026).
Does PT Murni Sadar Tbk pay a dividend?
PT Murni Sadar Tbk currently shows a dividend yield of about 0.25% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of PT Murni Sadar Tbk (MTMH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PT Murni Sadar Tbk it is 463.97 IDR per share (as of Sep 24, 2026), against a price of 950.00 IDR. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is PT Murni Sadar Tbk stock overvalued or undervalued in 2026?
As of Sep 24, 2026, MTMH trades above its calculated fair value: price 950.00 IDR, fair value 463.97 IDR, a gap of about −51% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MTMH?
No. The price is what the market pays today (950.00 IDR); the fair value is what the company's own numbers justify (463.97 IDR). For PT Murni Sadar Tbk the two are 486.03 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is PT Murni Sadar Tbk worth?
The market values PT Murni Sadar Tbk at about 2.0T IDR (market capitalisation, as of Sep 24, 2026). Per share that is 950.00 IDR; our models calculate a fair value of 463.97 IDR per share.
What do the bullish and bearish scenarios say about MTMH?
Our models span a range for PT Murni Sadar Tbk: cautious scenario 347.98 IDR, base 463.97 IDR, optimistic 579.96 IDR per share (as of Sep 24, 2026, price 950.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MTMH?
PT Murni Sadar Tbk trades at a price-to-earnings ratio of 48.3 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 463.97 IDR is built from several models across several years. Other multiples: P/B 1.3, P/S 1.3, EV/EBITDA 8.1.
How solid is the balance sheet of PT Murni Sadar Tbk (MTMH)?
Balance-sheet figures for PT Murni Sadar Tbk (as of Sep 24, 2026): return on equity 2.7%, debt of 0.30 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is MTMH from its 52-week high?
PT Murni Sadar Tbk trades at 950.00 IDR, about 31% below its 52-week high of 1,387 IDR and 7% above the low of 890.00 IDR (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 463.97 IDR is for.
Which stocks are comparable to PT Murni Sadar Tbk?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PT Murni Sadar Tbk stock attractive at the current price?
The data as of Sep 24, 2026: price 950.00 IDR, calculated fair value 463.97 IDR (−51%), Quality Score 45/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MTMH calculated?
We run PT Murni Sadar Tbk through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 463.97 IDR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. PT Murni Sadar Tbk itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PT Murni Sadar Tbk (MTMH)?
The closing price on Sep 24, 2026 was 950.00 IDR. Our model-based fair value is 463.97 IDR, about −51% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PT Murni Sadar Tbk right now?
The price sits above even our optimistic bull case (579.96 IDR). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of PT Murni Sadar Tbk
How large is the market capitalisation of PT Murni Sadar Tbk (MTMH)?
The market capitalisation of PT Murni Sadar Tbk is 2.0T IDR (≈ $110M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PT Murni Sadar Tbk (MTMH)?
The price-to-sales ratio of PT Murni Sadar Tbk is 1.55 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of PT Murni Sadar Tbk (MTMH)?
Earnings per share at PT Murni Sadar Tbk are 19.68 IDR (price ÷ EPS = P/E 48.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of PT Murni Sadar Tbk (MTMH)?
The dividend yield of PT Murni Sadar Tbk is 0.3% (payout 12.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of PT Murni Sadar Tbk (MTMH)?
The net margin of PT Murni Sadar Tbk is 3.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PT Murni Sadar Tbk (MTMH)?
The return on equity (ROE) of PT Murni Sadar Tbk is 2.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PT Murni Sadar Tbk (MTMH)?
On an EBIT basis the return on assets of PT Murni Sadar Tbk is 7.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PT Murni Sadar Tbk (MTMH)?
The operating margin of PT Murni Sadar Tbk is 7.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PT Murni Sadar Tbk (MTMH)?
Revenue at PT Murni Sadar Tbk is growing +22.9% versus a year earlier (3y avg +18.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at PT Murni Sadar Tbk (MTMH)?
Earnings per share at PT Murni Sadar Tbk are growing −21.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does PT Murni Sadar Tbk (MTMH) generate?
The free cash flow of PT Murni Sadar Tbk is −94.7B IDR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does PT Murni Sadar Tbk (MTMH) carry?
The net debt of PT Murni Sadar Tbk is 747B IDR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch PT Murni Sadar Tbk in the live analysis
One click puts PT Murni Sadar Tbk on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
